以奥沙利铂为主介入治疗结直肠癌肝转移的效果

Therapeutic efficacy of hepatic arterial infusion chemotherapy based on oxaliplatin for colorectal cancer liver metastases

目的:探讨以奥沙利铂为主的肝动脉灌注化疗对结直肠癌多发肝转移患者的治疗效果.方法:经肝动脉灌注化疗的结直肠癌多发肝转移患者26例为治疗组,共行肝动脉灌注及栓塞治疗58次,药物包括奥沙利铂130mg/m2,亚叶酸钙200mg/m2,5-FU750mg/m2.同期进行改良FOLFOX4方案全身化疗结直肠癌肝转移患者20例为对照组,观察治疗前后患者近期疗效、全身情况变化情况以及化疗后毒性反应.结果:治疗组近期疗效为57.7%,好于对照组的40.0%(P<0.05);治疗组Karmofsky评分提高率高于治疗前(P<0.05).对照组低于治疗前(P<0.05);治疗组毒副作用如恶心呕吐较对照组轻(P<0.05).结论:与FOLFOX4方案相比,以奥沙利铂为主的肝动脉灌注化疗能提高结直肠癌多发肝转移患者的近期疗效.

AIM： To evaluate the efficacy of hepatic arterial infusion chemotherapy （HAIC） based on oxaliplatin for treatment of the patients with multiple liver metastases from colorectal cancer. METHODS： Twenty-six patients （treatment group） with multiple liver metastases from colorectal cancer were treated 58 times by HAIC and embolotherapy, and chemotherapeutic agents used were oxaliplatin 130 mg/m^2, leucovorin 200 mg/m^2, 5-fluorouracil 750 mg/m^2. Meanwhile, 20 patients （control group ） were treated with modified FOLFOX4 regimen. Preliminary eflqcacy, change of body state and post-chemotherapy toxic reaction were observed and compared between the 2 groups. RESULTS： Preliminary efficacy of treatment group was prior to that of control group obviously （ 57. 7% vs 40. 0% , P〈0.05 ） ; Karmofsky scores were raised after treatment in treatment group （P〈0.05 ）, while they were degraded in control group （ P 〈 0. 05 ） ; side effects of treatment group were lighter than those of control group, such as nausea and vomiting （ P 〈 0. 05 ）. CONCLUSION ： Compared with FOLFOX4 regimen, HAIC based on oxaliplatin can enhance preliminary therapeutic efficacy.